Search / Trial NCT00000139

Herpetic Eye Disease Study (HEDS) II

Launched by NATIONAL EYE INSTITUTE (NEI) · Sep 23, 1999

Trial Information

Current as of December 09, 2024

Completed

Keywords

Herpes Simplex Stromal Keratitis

ClinConnect Summary

Infection of the eye by herpes simplex virus (HSV) is a leading cause of corneal blindness in the United States and other countries. The infection can lead to corneal scarring and neovascularization, permanent endothelial dysfunction and corneal edema, secondary glaucoma, and cataract. Despite the availability of topical antiviral agents that are highly active against HSV keratitis, there is still no known effective method for reducing the frequency of recurrence or severity of stromal keratitis and iridocyclitis. In addition, the prognosis is poor for recovery of good vision following pene...

Gender

ALL

Eligibility criteria

  • Protocol-specific criteria are noted in the description above.

About National Eye Institute (Nei)

The National Eye Institute (NEI), part of the U.S. National Institutes of Health (NIH), is dedicated to conducting and supporting innovative research to understand, prevent, and treat eye diseases and vision disorders. As a leading sponsor of clinical trials, NEI aims to advance knowledge in ocular health through rigorous scientific inquiry and collaboration with researchers, healthcare professionals, and institutions. By fostering the development of new therapies and technologies, NEI plays a pivotal role in enhancing the quality of life for individuals affected by visual impairments and eye conditions.

Locations

San Francisco, California, United States

Atlanta, Georgia, United States

Chicago, Illinois, United States

New Orleans, Louisiana, United States

New York, New York, United States

Philadelphia, Pennsylvania, United States

Houston, Texas, United States

Milwaukee, Wisconsin, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials